X

News

Vamorolone (VBP15) First-in-patient Studies in Duchenne Muscular Dystrophy Published

Rockville, MD –  2 October 2018
A clinical trial of vamorolone in 48 boys with Duchenne muscular dystrophy entitled “Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug” has been More >

More >

ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy

Rockville, MD –  22 August 2018
ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy. More >

More >

Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy

Rockville, MD – 26 June 2018
Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy.

More >

More >

Finalists Selected – 3rd Annual BioHealth Capital Region Crab Trap Competition

– Winner to be announced during 2018 BioHealth Capital Region Forum –

ROCKVILLE, MARYLAND, April 12, 2018 – Five companies have been selected to present to a panel of investor judges and an audience of industry leaders during the 2018 More >

ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

ROCKVILLE, Maryland, March 24, 2017

ReveraGen BioPharma Inc, a privately held corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for vamorolone (VBP15) for the treatment of patients with Duchenne muscular dystrophy. This designation

More >

Actelion obtains an option vamorolone from ReveraGen

Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side effects associated with glucocorticoid therapy.
ALLSCHWIL, SWITZERLAND, and ROCKVILLE (MD), USA

More >

ReveraGen BioPharma Inc Initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy

Enrollment has begun in the Phase 2a clinical trial of vamorolone (VBP15) in the treatment of boys with Duchenne muscular dystrophy (DMD). The Phase 2a trial sponsored by ReveraGen BioPharma, is an open-label, multiple ascending dose study that will be

More >

ReveraGen BioPharma Receives $3M for Phase 2 Studies of Vamorolone in Duchenne

PPMD is thrilled to see the continued progress of VBP-15, now known as Vamorolone. Progress to date includes a first in-human study of healthy volunteers and animal data which suggests it has none of the side effects of steroids, does

More >

Parent Project Muscular Dystrophy and Foundation to Eradicate Duchenne Award $1 Million Grant to ReveraGen BioPharma

Parent Project Muscular Dystrophy (PPMD) and Foundation to Eradicate Duchenne (FED) today announced that they will award ReveraGen BioPharma (ReveraGen) a $1 million grant. The grant will help fund ReveraGen’s VBP15, a combined action drug that

More >

ReveraGen BioPharma Announces Start of Phase 1 Clinical Trial of VBP15 Dissociative Steroid Drug

ReveraGen BioPharma today announced the start of a Phase 1, first-in-human, clinical trial of a novel dissociative steroidal drug, VBP15, under development for Duchenne muscular dystrophy. Recruitment in the trial is underway, with the initial doses in the first volunteers

More >